GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biostar Pharmaceuticals BSPM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2016

Revenue

$2.4m

FY2014FY2016

Net income

−$5.7m

FY2014FY2016

Free cash flow

$4.9m

FY2014FY2016

Shareholders' equity

$36.9m

FY2014FY2016

Income statement

Fiscal years

FY2016FY2015FY2014
Revenue$2.4m$27.1m$61.4m
Gross profit$915,174$11.1m$30.3m
Research and development$1.1m$4.0m$2.8m
Operating income−$3.6m−$23.8m−$1.3m
Net income−$5.7m−$25.1m$4.8m
Diluted earnings per share-2.23-11.362.21

Balance sheet

At each fiscal year end

FY2016FY2015FY2014
Total assets$42.5m$51.4m$81.2m
Cash and short-term investments$173,290$38,898$1.7m
Total liabilities$5.6m$7.1m$8.9m
Debt$2.3m$2.8m$3.1m
Shareholders' equity$36.9m$44.3m$72.3m
Shares outstanding3m2m2m

Cash flow

Fiscal years

FY2016FY2015FY2014
Cash from operations$4.9m$5.9m$3.3m
Capital spending—−$59,475−$2.9m
Free cash flow$4.9m$5.8m$441,414

Latest quarters

By quarter end

Sept 2017Jun 2017Mar 2017Dec 2016Sept 2016Jun 2016Mar 2016Dec 2015
Revenue——$317,794$317,794$644,933$620,138$801,627$1.8m
Gross profit——−$36,747−$36,747$308,063$298,888$344,970$768,025
Operating income−$573,000−$1.5m−$1.0m$5.9m−$2.0m−$6.9m−$669,000−$20.1m
Net income−$125,000−$1.4m−$1.0m$3.4m−$1.6m−$6.9m−$620,000−$23.2m
Diluted earnings per share-0.05-0.52-0.381.33-0.61-2.70-0.24-10.50
Cash from operations—$4.0m—$4.0m———$6.0m
Capital spending—−$4.0m——————
Free cash flow—$0——————
Total assets$41.4m$40.8m$41.5m$42.5m$40.6m$42.1m$50.4m$51.4m
Cash and short-term investments$364,973$407,410$483,858$173,290$659,359$207,110$91,482$38,898
Debt$2.4m$2.4m$2.3m$2.3m$2.4m$2.4m$2.5m$2.8m
Shareholders' equity$36.1m$35.5m$36.2m$36.9m$34.0m$35.8m$44.0m$44.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-64.4%-51.8%-8.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin40.7%47.3%56.9%62.2%
Operating margin-92.6%-19.6%-10.6%4.8%
Net margin-104.4%-17.5%-11.6%1.5%

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-90%900%-99%9900%7%4103019%22837%-58%-40%15%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 7-to-1 reverse split · 5 Feb 2016
  • 3-to-1 reverse split · 4 Apr 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.